High molecular levan inhibited the growth of lymphoma in AKR mice and 3LL carcinoma in C57 B1 mice. The inhibitory effect was expressed in a lesser incidence and smaller size of tumors and in a higher survival rate in comparison with untreated controls. The inhibition of both tumors depended on the dose of levan, the size of the inoculum (number of viable malignant cells injected) and the timing and site of administration. The tumor growth inhibiting activity was more pronounced with larger doses and was inversely proportional to the size of the inoculum. Levan injection into the tumor site were more effective than systemic (intraperitoneal) treatment. Levan injection in the tumor site begun on the day of tumor cell innoculation was more effective than when treatment was started later. In contrast, levan treatment begun before tumor inoculation enhanced tumor growth. Machrophages and/or neutrophils played a role in the destruction of tumor cells.
|Pages (from-to)||337-340 + 386|
|State||Published - 1977|